# Anthropic Steps Into Drug Discovery With Claude Science

> Some announcements look, on paper, like a simple product-line expansion, but in reality redraw the boundaries of an entire industry. That's the

- Author: Maxime Marquette
- Publisher: MadMax (https://mad-max.co)
- Section: Profile
- Published: 2026-07-06
- Canonical URL: https://mad-max.co/en/article/anthropic-se-lance-dans-la-decouverte-de-medicaments-avec-claude-science

## Introduction: when an AI company wants to cure neglected diseases

### An announcement made at a science-focused event

Some announcements look, on paper, like a simple product-line expansion, but in reality redraw the boundaries of an entire industry. That's the case with **Anthropic's** reveal at its event called "The Briefing: AI for Science," where the company unveiled **Claude Science**, a workspace built specifically for **researchers**, capable of consolidating fragmented tools and **datasets**, and automatically generating **scientific** figures and visuals.

But the announcement didn't stop there. **Anthropic** also revealed its intention to develop its own drugs, targeting **neglected diseases** largely ignored by the traditional pharmaceutical industry, a project led by **Eric Kauderer-Abrams**, the company's head of life sciences. An artificial intelligence company suddenly becoming a potential player in pharmaceutical **discovery**: that's worth pausing on.

### A strategic vagueness that's already raising eyebrows

What stands out immediately is how few details **Anthropic** has offered about which **diseases** this new program will actually target. The company hasn't answered questions about specific therapeutic targets, nor about potential partnerships for **clinical** **trials** or manufacturing, leaving notable uncertainty about the real feasibility and actual timeline of this ambitious project.

This vagueness isn't trivial in an industry where every announcement is scrutinized closely by experts accustomed to unfulfilled promises from the pharmaceutical sector and, more recently, to the spectacular but sometimes premature claims coming out of AI applied to **health**.

*I applaud Anthropic's ambition to tackle **neglected diseases**, a segment traditional pharmaceutical companies too often abandon for lack of sufficient profitability. But I remain cautious about the lack of concrete detail, a vagueness that could just as easily hide a strategy still taking shape as a carefully calibrated communications play.*

## Claude Science, a tool built for researchers

### Consolidating a fragmented scientific ecosystem

The core of the announcement remains **Claude Science**, presented as a digital workspace meant to simplify life for **researchers** juggling a growing pile of tools, **databases**, and incompatible formats. The tool promises to centralize these scattered resources, cutting down time lost on administrative and technical tasks in favor of actual **scientific** work.

This consolidation approach addresses a very real frustration, well documented across the scientific community, where a substantial share of **research** time today goes toward managing **data** rather than analyzing and interpreting the **results** themselves.

### Automatically generating scientific visuals

Another highlighted feature: **Claude Science's** ability to automatically generate figures and visual representations from raw **scientific** **data**, a task that traditionally eats up hours for **researchers** preparing publications or presentations for peers and funders.

This automation, if it delivers on its promise, could free up valuable time for **research** teams, letting them devote more resources to designing experiments rather than formatting **results** they've already obtained.

*I think this tooling dimension, less spectacular than the promise of new drugs, could actually have the most immediate and measurable impact on global **scientific** productivity, long before a single AI-developed drug ever reaches a patient.*

## The backdrop of a global race in scientific AI

### Anthropic joins already well-established players

By positioning itself in AI-assisted pharmaceutical **discovery**, **Anthropic** joins a race already underway among players like **Isomorphic Labs**, the **Google DeepMind** subsidiary, as well as **Insilico Medicine**, not to mention the growing investments from **OpenAI**, **Amazon**, and **Google** in tools dedicated to the life sciences.

This crowded competition shows just how much AI-assisted pharmaceutical **discovery** has become a major strategic battleground for Western tech giants, each trying to prove its models can speed up a process that's traditionally long, expensive, and uncertain.

### An unusual position: selling to future competitors

Anthropic's situation carries a notable quirk: the company already sells its software tools to established pharmaceutical labs, while potentially preparing to become a direct competitor of those very clients in drug **discovery**. This duality raises legitimate questions about how it will manage upcoming commercial conflicts of interest.

This unusual setup could force **Anthropic** to quickly clarify the boundaries between its role as a tools vendor and its ambition to become a full-fledged pharmaceutical developer, or risk having some longtime pharmaceutical clients grow wary of this dual role.

*I find this position both fascinating and commercially risky. Becoming simultaneously a tools supplier and a direct competitor of its own clients is a bold bet that could either propel Anthropic to the top of the sector or undermine the **trust** of its longtime pharmaceutical partners.*

## Expert voices calling for caution

### No AI-designed drug has cleared clinical trials yet

Professor **Matthew Todd**, a drug **discovery** specialist at **University College London**, points to an unavoidable reality: to date, no drug truly designed by artificial intelligence has successfully cleared the full course of **clinical** **trials** and secured complete regulatory approval. The road ahead, in his view, remains long, despite the undeniable progress AI has brought to certain stages of the process.

This warning isn't a dismissal of AI's potential in this field, but a useful reminder that pharmaceutical **research** remains bound by regulatory and experimental constraints that raw computing power, however impressive, cannot bypass.

### The irreplaceable weight of real-world experimentation

Professor **Frank von Delft**, a specialist in structural chemical biology at **Oxford**, notes that current AI models "haven't yet managed to make experiments unnecessary," and that **Anthropic** will necessarily "have to spend heavily on experiments" in the physical world to validate its computer-generated **hypotheses**.

This remark points to a fundamental truth too often downplayed in today's tech discourse: artificial intelligence can speed up hypothesis generation and **data** **analysis**, but it doesn't replace the rigorous experimental validation demanded by **health** authorities before any treatment reaches the market.

*I think these warnings from established experts need to be taken very seriously, without tipping into total skepticism. The history of technology is full of examples where legitimate short-term criticism didn't stop real medium-term progress, provided the **scientific** fundamentals were respected.*

## The role of pharmaceutical experts in this pivot

### Active recruiting from the established industry

According to **Namshik Han**, co-founder of biotech firm **CardiaTec** and a researcher at the University of **Cambridge**, **Anthropic** is actively recruiting staff from major pharmaceutical companies like **AstraZeneca**, **Novo Nordisk**, and **GSK**, as well as from academia, a strategy that signals a serious intent to build solid internal **scientific** expertise rather than simply selling software tools.

This cross-recruitment between traditional pharmaceutical giants and tech companies illustrates growing porousness between two historically distinct sectors, each now feeding its expertise into the other in a convergence accelerated by the promises of AI applied to **health**.

### Physical infrastructure already under construction

For more than a year, **Anthropic** has quietly built physical experimental labs and ramped up job postings in the life sciences, logistical groundwork suggesting the **Claude Science** announcement and the pharmaceutical development program aren't a sudden improvisation, but the culmination of a strategy developed over several quarters.

This upfront preparation lends credibility to the project, even though it guarantees nothing about its eventual success, given how considerable the **scientific** and regulatory challenges of pharmaceutical development remain, regardless of how sophisticated the digital tools deployed earlier in the process might be.

*I find it reassuring that Anthropic has invested in real physical labs rather than settling for a purely marketing announcement. That suggests serious intent, even though the road to an actually approved first drug remains, by the experts' own admission, a distant prospect.*

## Neglected diseases, a strategic and ethical choice

### A segment abandoned by traditional industry

The choice to target **neglected diseases** rather than more lucrative conditions is an interesting strategic move. These **diseases**, often concentrated in lower-income regions, traditionally suffer from chronic underinvestment by major pharmaceutical companies, more driven by commercial potential than by the real health urgency of the **populations** affected.

By tackling this neglected segment, **Anthropic** positions itself in a space with weaker direct commercial competition, while building a positive public image, a calculation that can be both sincerely altruistic and strategically advantageous for the company's reputation.

### A credibility test for AI's promise to serve the common good

This choice also puts **Anthropic** in front of an important credibility test: if the company genuinely manages to advance treatment for neglected **diseases** through artificial intelligence, it would demonstrate a concrete use of large language models for the common good, beyond more conventional commercial applications like chatbots or productivity tools.

Conversely, a failure or a quiet abandonment of this project after a splashy media announcement would fuel growing skepticism toward the sometimes-exaggerated promises of the AI industry about its ability to solve complex, urgent human problems.

*I want to believe in the sincerity of this move on **neglected diseases**, while staying aware it also serves Anthropic's image interests. The two aren't mutually exclusive, and I think this project should be judged on its concrete **results** rather than on the intentions stated at the moment of the announcement.*

## The West facing global technological competition

### A scientific battle with geopolitical stakes

This announcement from **Anthropic** fits within a broader context of global technological competition, where Western companies are trying to hold onto a strategic edge against rivals, particularly Chinese ones, investing heavily in AI applied to science and **health**. Keeping Western **scientific** leadership over these disruptive technologies remains a stake that reaches well beyond the pharmaceutical sector alone.

This geopolitical dimension partly explains why companies like **Anthropic**, **OpenAI**, or **Google DeepMind** enjoy implicit, if not explicit, support from Western governments, who understand that mastery of **scientific** artificial intelligence represents a major strategic asset for decades to come.

### Why the West must stay ahead in this race

It's essential that Western democracies keep their lead in this field, since the applications of **scientific** artificial intelligence go well beyond pharmaceutical questions alone to touch on national security, economic competitiveness, and global geopolitical influence against authoritarian regimes that don't hesitate to weaponize their own technological advances for power.

This technological race, however commercial it may appear on the surface, is therefore part of a broader civilizational stake, where maintaining Western **scientific** leadership partly determines the collective ability to set the ethical and regulatory standards that will govern the future use of these powerful technologies.

*I firmly believe Western **scientific** leadership in artificial intelligence applied to **health** isn't just a commercial question, it's a matter of strategic sovereignty. Ceding this ground to rivals less concerned with ethics would be a historic mistake the West cannot afford to make.*

## The regulatory challenges awaiting Anthropic

### A long and rigorous approval path

Even assuming **Anthropic** manages to identify promising drug candidates using its AI tools, the company will still have to navigate the standard regulatory approval process, including preclinical **trials**, then three successive phases of **clinical** trials, a process that generally takes several years regardless of how sophisticated the digital tools used earlier in the process may be.

This regulatory path, designed to guarantee patient safety, cannot be meaningfully shortened by artificial intelligence, which mainly plays a role earlier on in the design and candidate-molecule identification phase, without being able to replace the safety checks required by health agencies.

### Funding, an underestimated obstacle

Beyond regulation, funding pharmaceutical development remains a major challenge, with every phase of **clinical** **trials** requiring considerable investment with no guarantee of eventual success. **Anthropic**, despite its substantial financial resources from its tech business, will need to demonstrate it can sustain funding for this kind of project over the long haul, a timeline very different from what's typical in the tech industry.

This cultural gap between the fast pace of tech innovation and the slow timeline of pharmaceutical **research** could be one of the biggest adaptation challenges for a company historically rooted in developing language models rather than classic biomedical research.

*I think this gap in pace between tech culture and pharmaceutical culture will be Anthropic's real test in the years ahead. Learning to patiently wait for the **results** of **clinical** **trials**, without caving to the usual pressure for fast quarterly results, will require a new kind of discipline for this company.*

## What this means for patients with neglected diseases

### Measured hope rather than an immediate promise

For patients and communities affected by **neglected diseases**, this announcement should be met with measured hope rather than an expectation of immediate solutions. The concrete benefit of this kind of initiative, if it succeeds, will likely take several years to materialize, according to industry experts' own estimates, which mention "the better part of a decade" before a treatment born from this approach actually reaches patients.

This long timeline shouldn't discourage interest in this kind of project, but it does demand constant vigilance to ensure the initial promises actually translate, over time, into concrete, accessible treatments rather than a communications exercise with no tangible follow-through.

### An ethical responsibility to monitor over time

The **scientific** community and public **health** organizations will have an essential role to play in monitoring, over the long term, whether **Anthropic** keeps its commitments to populations affected by neglected **diseases**, rather than getting distracted by more commercially profitable projects once the initial media attention fades.

This long-term vigilance is the best guarantee that today's stated ambition translates, in the years ahead, into real benefits for the most vulnerable patients rather than a promise abandoned along the way in favor of more immediate commercial goals.

*I'm committing to closely follow how this project unfolds in the years ahead, convinced that the real measure of its success won't be found in today's press **headlines**, but in the treatments actually delivered, or not, to affected patients by the end of the decade.*

## Reactions from the established pharmaceutical industry

### Between curiosity and cautious skepticism

Major pharmaceutical companies, already clients of some of **Anthropic's** tools, are watching this announcement with a mix of curiosity and cautious skepticism. Some publicly praise the potential of AI tools to speed up their own **research**, while others quietly wonder about the long-term competitive implications of a tech company simultaneously becoming a supplier and a potential rival.

This ambivalence from the established industry reflects a broader period of transition, where the traditional lines between technology and pharmaceuticals are gradually blurring, forcing every player to rethink its strategic alliances and business partnerships in a competitive landscape being reshaped in real time.

### A signal that accelerates the whole sector

Whatever the precise outcome of **Anthropic's** project, this announcement is already acting as an acceleration signal for the entire sector, pushing other tech and pharmaceutical companies to invest more heavily in similar approaches, wary of falling behind in a technological race whose stakes go well beyond any single company.

This collective acceleration could, over time, benefit patients as a whole, regardless of whether it's specifically **Anthropic** that manages to develop the first drug born from this new generation of AI tools applied to biomedical **research**.

*I think the real victory of this announcement, regardless of Anthropic's specific success or failure, will be having pushed the entire global pharmaceutical ecosystem toward faster adoption of artificial intelligence in service of **diseases** too long neglected by the market alone.*

## The question of public trust in medical AI

### A legitimate skepticism inherited from earlier announcements

The public, much like the **scientific** community, remains marked by a string of earlier announcements in AI applied to **health** that haven't always delivered on their initial promises within the stated timelines. This recent history justifies healthy skepticism toward any new announcement, however promising it looks on paper, until concrete clinical **results** come to confirm it.

This skepticism shouldn't turn into blanket rejection of every innovation, but rather into a demand for ongoing transparency from companies like **Anthropic**, who will need to regularly document their actual progress rather than settling for one-off announcements without verifiable follow-up.

### The importance of transparent, ongoing communication

To earn public **trust** on a subject as sensitive as **health**, **Anthropic** will need to adopt transparent, regular communication about its program's actual progress, including any setbacks as much as its successes, a practice still too rare in a tech industry accustomed to talking only about its most spectacular wins.

This ongoing transparency will ultimately be a deciding factor in distinguishing tech companies genuinely committed to improving public **health** from those using these noble themes mainly for marketing and brand-image purposes.

*I'm calling on Anthropic to show exemplary transparency on this project, including on its potential failures. It's this honesty, more than any technical feat announced with fanfare, that will determine the company's lasting credibility on this sensitive terrain of human **health**.*

## Implications for global academic research

### A potentially democratizing tool for smaller labs

Beyond major pharmaceutical companies, **Claude Science** could potentially benefit academic **research** labs with more modest resources, giving them access to **data**-consolidation and visual-generation tools previously reserved for the best-funded institutions. This potential democratization deserves praise if it holds up in the daily practice of **researchers**.

Still, actual access to these tools will largely depend on the business model **Anthropic** chooses, particularly on the question of usage costs for academic institutions with budgets often far smaller than those of private pharmaceutical giants.

### Potential to accelerate fundamental research

If **Claude Science's** promises hold up, the tool could also accelerate fundamental **research** well beyond drug development alone, easing the daily work of **researchers** in fields as varied as biology, chemistry, or neuroscience, where managing complex **data** often represents a real drag on scientific productivity.

This potential cross-cutting acceleration of fundamental **research** could, in the long run, represent the most significant impact of this announcement, far beyond the more uncertain short-term question of **Anthropic's** actual drug development.

*I remain optimistic about this academic dimension of the project, which strikes me as the strongest bet in the short term. Helping under-resourced **researchers** save time on tedious **data** management is a concrete, measurable benefit, and a far more immediate one than the still-distant promise of a revolutionary drug.*

## The still-vague business model behind this pivot

### How to fund such a costly dual venture

One central question remains largely unanswered publicly: how does **Anthropic** plan to simultaneously fund the costly development of **Claude Science** as a commercial product and an internal pharmaceutical **research** program whose returns, if they ever materialize, likely won't show up for several years. This dual strategic spending demands considerable financial resources, even for a company as well capitalized as Anthropic.

The company's investors will also need to accept this long timeline, radically different from the fast profitability cycles typically expected in the tech sector, a cultural shift that could eventually weigh on the company's future strategic choices if **results** take too long to show up concretely.

### A diversification that splits financial analysts

Some financial analysts praise this diversification as a smart long-term strategy, letting **Anthropic** reduce its dependence on subscription and language-model usage revenue alone. Others, more skeptical, fear an excessive spread of resources and management attention, at the expense of the company's historic core business in large language models.

This debate between advocates of strategic diversification and defenders of focusing on the historic core business regularly recurs throughout the history of major tech companies, without any universal answer clearly emerging from the sector's past experiences.

*I understand some analysts' reservations about this ambitious diversification, but I also think a company as well-funded as Anthropic can afford to bet on the long term, provided it communicates honestly with its partners and staff about realistic timelines for returns.*

## The precedent of big unfulfilled tech promises

### A recent history dotted with disappointments

The tech sector is full of examples of spectacular health-related announcements that, in hindsight, never fully delivered on their initial promises within the stated timeline, whether AI-powered automated diagnostics projects or personalized medicine platforms once billed as revolutionary before running into implementation challenges far bigger than initially expected.

This recent history, without automatically discrediting **Anthropic's** project, calls for constant methodological **caution** toward any new tech announcement in the sensitive field of **health**, where human stakes demand a higher standard of rigor than what's usually tolerated in lighter tech sectors.

### What could set Anthropic apart from its predecessors

Despite this historically justified pattern of **caution**, several elements potentially set **Anthropic's** approach apart: actively recruiting experienced pharmaceutical experts, real physical investment in labs, and explicit public acknowledgment, voiced by its own leadership, of AI's current limits in this field, rather than a purely promotional, nuance-free message.

This combination of **factors**, while not guaranteeing the project's ultimate success, at least suggests a more methodical, less purely communications-driven approach than some earlier tech announcements in **health**, an encouraging signal even though it's no guarantee of success.

*I choose to reserve final judgment on Anthropic, neither naive about the scale of the ambition on display, nor cynical enough to reject on principle any serious new attempt to apply artificial intelligence to **health** problems this urgent yet this neglected.*

## Conclusion: an ambition worth watching with a critical eye

### A bold bet whose outcome remains uncertain

**Anthropic's** entry into drug **discovery**, driven by the launch of **Claude Science** and a program targeting **neglected diseases**, is a bold bet worth following with a mix of sincere interest and critical vigilance. The experts consulted agree on one essential point: the road to an actually approved first drug remains long, uncertain, and subject to regulatory and experimental constraints that artificial intelligence alone cannot bypass.

This announcement nonetheless confirms that the global race in **scientific** artificial intelligence is intensifying, with stakes that reach well beyond commercial considerations to touch on questions of Western technological leadership against strategic rivals determined not to fall behind.

### Time will be the best judge of this ambition

Only time will tell whether this initiative from **Anthropic** translates into real medical advances for **populations** too long neglected by the traditional pharmaceutical industry, or whether it remains, like so many tech announcements before it, an ambitious promise whose realization took far longer than the initial enthusiasm of its media launch suggested.

*I'm closing this profile convinced that Anthropic is playing a hand that's both noble and risky here. I choose to praise the ambition without naivety, keeping in mind that between the announcement and the first drug actually delivered to patients, years of rigorous, uncertain work still remain to be done.*

**By Maxime Marquette, columnist**

## Columnist's transparency note

### Editorial stance

I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies.

I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events.

### Method and sources

This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here.

**Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies.

**Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations.

When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**.

### Nature of the analysis

The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted.

My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors.

This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text.

## Sources

### Primary sources

- The Verge — Anthropic launches Claude Science and a pharmaceutical development program, July 3, 2026

- India Today — What to know about Anthropic's drug discovery program, July 1, 2026

### Secondary sources

- John Sviokla — Daily AI news, July 1, 2026

- AI to ROI — AI news and analysis, July 2026

- Reuters — Artificial intelligence news

- YouTube — Video coverage of the Claude Science announcement

---

Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/anthropic-se-lance-dans-la-decouverte-de-medicaments-avec-claude-science